Celularity Inc. has submitted an application to the U.S. Food and Drug Administration (FDA) for orphan drug designation for PDA-002, its placental-derived cell therapy.

A clinical trial has been initiated for an innovative drug candidate, 23ME-01473, developed by 23andMe Holding Co., a prominent entity in human genetics and biopharmaceuticals.

Significant advancements have been observed in the treatment of thyroid eye disease (TED) with lonigutamab, a humanized monoclonal antibody.

Inhalon Biopharma, a company in the clinical stage, has revealed initial findings from a pivotal Phase 1b clinical trial.

Antennova, a biopharmaceutical firm, has reached a significant milestone with the completion of the initial dosing group in a Phase I clinical trial for ATN-031.

Public Health Vaccines has initiated a Phase 1 clinical trial for a novel vaccine candidate, PHV01, which targets the Marburg virus.

Theratechnologies Inc., has progressed to a higher dosage level in the third phase of its clinical trial for a drug called sudocetaxel zendusortide.

Blue Lake Biotechnology has released early findings from a Phase 1/2a clinical trial for BLB201.

Andelyn Biosciences has teamed up with Grace Science, LLC, to facilitate the technical transfer and production of GS-100, an AAV NGLY1 gene therapy for clinical trials.

Brain Trust Bio (BTB), a pioneering company in the field of central nervous system (CNS) disease treatment, has been granted the go-ahead to initiate Phase I clinical trials.

Astria Therapeutics has reported promising preliminary results from the ALPHA-STAR Phase 1b/2 clinical trial of STAR-0215.

Stoke Therapeutics has reported significant findings from its Phase 1/2a clinical trials and open-label extension studies for STK-001.